A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers : positive impacts of the Lu177- PSMA treatment in the advanced stage of prostate cancer

Thumbnail Image
Files
Vyas, M. (2019).pdf (1.56 MB)
Supplementary material
Other Title
Authors
Vyas, Madhusudan
Fagan, Jessica
Shaikh, Shamim
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2019-08-31
Supervisors
Type
Conference Contribution - Oral Presentation
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
New Zealand
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
ANZSRC Field of Research Code (2020)
1112 Oncology and Carcinogenesis
110313 Nuclear Medicine
Citation
Vyas, M., Fagan, J., & Shaikh, S. (2019, September). A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers: Positive impacts of the Lu177- PSMA Treatment in the advanced stage of Prostate cancer. Paper presented at the NZIMRT/ANZSNM-2019, Rotorua, New Zealand.
Abstract
Objective To evaluate the impact/effects of Lutetium-177-PSMA based treatment in improving the quality of life in patients with advanced stage of prostate cancer (mCRPC) Methodology Epidemiology (Global data) Epidemiology (NZ Data) Diagnosis and staging Treatment plan Metastatic disease(mCRPC) Metastatic disease(mCRPC) Metastatic disease(mCRPC) treatment algorithm Metastatic disease(mCRPC) treatment review of literature Prostate specific membrane antigen (PSMA) and mCRPC Various Prostate specific membrane antigen (PSMA) ligands and radionuclides suitable for labelling Lu-177 PSMA based Metastatic disease(mCRPC) treatment review of literature Lu-177-PSMA Treatment outcomes Lu-177 based therapeutic radiopharmaceuticals based treatment outcomes Physiological outcomes of the treatment, at our clinical site QoL, Pain and PSA levels; relative comparison PSA response and QoLoutcomes to Lu-177-PSMA, at our clinical site Third line treatment v/s Lu-177-PSMA Third line treatment v/s Lu-177-PSMA;Feedback from patients Conclusion Reference
Publisher
Permanent link
https://hdl.handle.net/10652/4714
Link to ePress publication
DOI
Copyright holder
Authors
Copyright notice
All rights reserved
Copyright license
Available online at
This item appears in:
Health Sciences Conference Papers